At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 16 Apr 1996 Discontinued-II for Congestive heart failure in USA (PO)
- 16 Apr 1996 Discontinued-II for Hypertension in USA (PO)
- 03 Mar 1995 Phase-II clinical trials for Congestive heart failure in USA (PO)